ACAD – ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.ACAD
$14.73Name : ACADIA Pharmaceuticals Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,456,801,792.00
EPSttm : 1.36
ACADIA Pharmaceuticals Inc.
$14.73
1.10%$0.16Float Short %
9.44
Margin Of Safety %
46
Put/Call OI Ratio
0.19
EPS Next Q Diff
0.19
EPS Last/This Y
-0.78
EPS This/Next Y
0.43
Price
14.73
Target Price
24.68
Analyst Recom
1.95
Performance Q
-15.92
Relative Volume
0.7
Beta
0.5
Ticker: ACAD
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | ACAD | 16.8 | 0.23 | 0.26 | 27807 |
| 2025-03-24 | ACAD | 17.22 | 0.18 | 0.03 | 18776 |
| 2025-03-25 | ACAD | 17.1 | 0.17 | 0.16 | 19957 |
| 2025-03-26 | ACAD | 17.03 | 0.17 | 0.16 | 20247 |
| 2025-03-27 | ACAD | 17.17 | 0.17 | 0.04 | 21511 |
| 2025-03-28 | ACAD | 17.06 | 0.17 | 0.02 | 21888 |
| 2025-03-31 | ACAD | 16.59 | 0.17 | 0.28 | 22162 |
| 2025-04-01 | ACAD | 16.31 | 0.18 | 0.04 | 23798 |
| 2025-04-02 | ACAD | 16.61 | 0.18 | 0.15 | 24520 |
| 2025-04-03 | ACAD | 16.11 | 0.18 | 0.57 | 24853 |
| 2025-04-04 | ACAD | 15.39 | 0.18 | 0.54 | 25015 |
| 2025-04-07 | ACAD | 14.64 | 0.19 | 0.17 | 25678 |
| 2025-04-08 | ACAD | 14.11 | 0.18 | 0.15 | 26254 |
| 2025-04-09 | ACAD | 14.99 | 0.18 | 0.68 | 27617 |
| 2025-04-10 | ACAD | 14.13 | 0.20 | 0.02 | 28787 |
| 2025-04-11 | ACAD | 14.57 | 0.18 | 0.27 | 30606 |
| 2025-04-14 | ACAD | 14.86 | 0.18 | 4.94 | 30604 |
| 2025-04-15 | ACAD | 14.99 | 0.19 | 0.64 | 30931 |
| 2025-04-16 | ACAD | 14.56 | 0.19 | 10.98 | 31226 |
| 2025-04-17 | ACAD | 14.72 | 0.19 | 0.13 | 31150 |
| 2025-04-18 | ACAD | 14.73 | 0.19 | 0.13 | 31150 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | ACAD | 16.82 | -131.9 | -3.6 | 0.57 |
| 2025-03-24 | ACAD | 17.23 | -131.9 | 1.5 | 0.57 |
| 2025-03-25 | ACAD | 17.11 | -131.9 | -2.1 | 0.57 |
| 2025-03-26 | ACAD | 17.03 | -131.9 | -1.9 | 0.57 |
| 2025-03-27 | ACAD | 17.18 | -131.9 | -0.3 | 0.57 |
| 2025-03-28 | ACAD | 17.07 | -131.9 | -2.1 | 0.57 |
| 2025-03-31 | ACAD | 16.60 | -131.9 | -4.3 | 0.57 |
| 2025-04-01 | ACAD | 16.32 | -131.9 | -3.1 | 0.57 |
| 2025-04-02 | ACAD | 16.62 | -131.9 | 0.7 | 0.57 |
| 2025-04-03 | ACAD | 16.11 | -131.9 | -4.7 | 0.57 |
| 2025-04-04 | ACAD | 15.37 | -131.9 | -6.6 | 0.57 |
| 2025-04-07 | ACAD | 14.62 | -133.5 | -7.0 | 0.57 |
| 2025-04-08 | ACAD | 14.10 | -133.5 | -5.4 | 0.57 |
| 2025-04-09 | ACAD | 14.97 | -133.5 | 6.0 | 0.57 |
| 2025-04-10 | ACAD | 14.13 | -133.5 | -7.7 | 0.57 |
| 2025-04-11 | ACAD | 14.56 | -133.5 | 2.5 | 0.57 |
| 2025-04-14 | ACAD | 14.86 | -133.5 | 0.9 | 0.57 |
| 2025-04-15 | ACAD | 14.99 | -126.8 | -0.3 | 0.57 |
| 2025-04-16 | ACAD | 14.56 | -118.2 | -4.6 | 0.58 |
| 2025-04-17 | ACAD | 14.73 | -118.2 | 0.0 | 0.58 |
| 2025-04-18 | ACAD | 14.73 | -118.2 | -1.3 | 0.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | ACAD | -2.34 | 13.48 | 8.70 |
| 2025-03-24 | ACAD | -2.34 | 13.80 | 8.70 |
| 2025-03-25 | ACAD | -2.34 | 13.80 | 8.70 |
| 2025-03-26 | ACAD | -2.34 | 13.80 | 8.72 |
| 2025-03-27 | ACAD | -2.66 | 13.80 | 8.72 |
| 2025-03-28 | ACAD | -2.66 | 13.80 | 8.72 |
| 2025-03-31 | ACAD | -2.66 | 13.43 | 8.72 |
| 2025-04-01 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-02 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-03 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-04 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-07 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-08 | ACAD | -2.63 | 13.43 | 8.72 |
| 2025-04-09 | ACAD | -2.90 | 13.43 | 8.72 |
| 2025-04-10 | ACAD | -2.90 | 13.43 | 9.44 |
| 2025-04-11 | ACAD | -2.90 | 13.43 | 9.44 |
| 2025-04-14 | ACAD | -2.90 | 13.47 | 9.44 |
| 2025-04-15 | ACAD | -2.90 | 13.47 | 9.44 |
| 2025-04-16 | ACAD | -2.90 | 13.47 | 9.44 |
| 2025-04-17 | ACAD | -2.90 | 13.47 | 9.44 |
| 2025-04-18 | ACAD | -2.90 | 13.47 | 9.44 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.02
Avg. EPS Est. Current Quarter
-0.03
Avg. EPS Est. Next Quarter
0.17
Insider Transactions
-2.9
Institutional Transactions
13.47
Beta
0.5
Average Sales Estimate Current Quarter
239
Average Sales Estimate Next Quarter
263
Fair Value
21.47
Quality Score
91
Growth Score
61
Sentiment Score
48
Actual DrawDown %
74.9
Max Drawdown 5-Year %
-77.2
Target Price
24.68
P/E
10.83
Forward P/E
15.53
PEG
9.03
P/S
2.57
P/B
3.35
P/Free Cash Flow
15.63
EPS
1.36
Average EPS Est. Cur. Y
0.59
EPS Next Y. (Est.)
1.02
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
23.64
Relative Volume
0.7
Return on Equity vs Sector %
10.9
Return on Equity vs Industry %
24.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
-1.3
ACADIA Pharmaceuticals Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 653
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
stock quote shares ACAD – ACADIA Pharmaceuticals Inc. Stock Price stock today
news today ACAD – ACADIA Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ACAD – ACADIA Pharmaceuticals Inc. yahoo finance google finance
stock history ACAD – ACADIA Pharmaceuticals Inc. invest stock market
stock prices ACAD premarket after hours
ticker ACAD fair value insiders trading